BRPI0514420A - peptìdeo, variante do mesmo, ou um sal farmaceuticamente aceitável do mesmo, composição, uso de um peptìdeo ou de uma variante de peptìdeo, substrato, e, métodos de tratamento ou prevenção de um infecção microbiana, e de tratamento de uma ferida em um indivìduo - Google Patents

peptìdeo, variante do mesmo, ou um sal farmaceuticamente aceitável do mesmo, composição, uso de um peptìdeo ou de uma variante de peptìdeo, substrato, e, métodos de tratamento ou prevenção de um infecção microbiana, e de tratamento de uma ferida em um indivìduo

Info

Publication number
BRPI0514420A
BRPI0514420A BRPI0514420-5A BRPI0514420A BRPI0514420A BR PI0514420 A BRPI0514420 A BR PI0514420A BR PI0514420 A BRPI0514420 A BR PI0514420A BR PI0514420 A BRPI0514420 A BR PI0514420A
Authority
BR
Brazil
Prior art keywords
peptide
variant
treating
substrate
pharmaceutically acceptable
Prior art date
Application number
BRPI0514420-5A
Other languages
English (en)
Inventor
Deborah O'neil
Original Assignee
Novabiotics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0418414.9A external-priority patent/GB0418414D0/en
Application filed by Novabiotics Ltd filed Critical Novabiotics Ltd
Publication of BRPI0514420A publication Critical patent/BRPI0514420A/pt
Publication of BRPI0514420B1 publication Critical patent/BRPI0514420B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

PEPTìDEO, VARIANTE DO MESMO, OU UM SAL FARMACEUTICAMENTE ACEITáVEL DO MESMO, COMPOSIçãO, USO DE UM PEPTìDEO OU DE UMA VARIANTE DE PEPTìDEO, SUBSTRATO, E, MéTODOS DE TRATAMENTO OU PREVENçãO DE UMA INFECçãO MICROBIANA, E DE TRATAMENTO DE UMA FERIDA EM UM INDIVìDUO A invenção refere-se a um peptídeo que compreende aminoácidos de acordo com a Fórmula (I):((X)~ 1~(Y)~ m~)~ n~ em que 1 e m s~o números inteiros de 0 a 10; X e Y, que podem ser iguais ou diferentes, são um aminoácido selecionado do grupo que consiste de aminoácidos hidrofóbicos e/ou aminoácidos catiónicos, para uso como um medicamento.
BRPI0514420-5A 2004-08-18 2005-08-18 Peptídeo, ou um sal farmaceuticamente aceitável do mesmo, e, uso de um peptídeo BRPI0514420B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB0418414.9A GB0418414D0 (en) 2004-08-18 2004-08-18 Peptide
GB0418414.9 2004-08-18
US7979505A 2005-03-14 2005-03-14
US11/079,795 2005-03-14
PCT/GB2005/003245 WO2006018652A2 (en) 2004-08-18 2005-08-18 Antimicrobial peptides comprising an arginine- and/or lysine-containing motif

Publications (2)

Publication Number Publication Date
BRPI0514420A true BRPI0514420A (pt) 2008-06-10
BRPI0514420B1 BRPI0514420B1 (pt) 2022-05-17

Family

ID=35907779

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514420-5A BRPI0514420B1 (pt) 2004-08-18 2005-08-18 Peptídeo, ou um sal farmaceuticamente aceitável do mesmo, e, uso de um peptídeo

Country Status (24)

Country Link
US (4) US7847059B2 (pt)
EP (5) EP1778720B1 (pt)
JP (1) JP5020078B2 (pt)
KR (1) KR101234780B1 (pt)
CN (3) CN101031583B (pt)
AT (1) ATE479704T1 (pt)
AU (1) AU2005273638B2 (pt)
BR (1) BRPI0514420B1 (pt)
CA (2) CA2575058C (pt)
CY (1) CY1113684T1 (pt)
DE (1) DE602005023315D1 (pt)
DK (2) DK1927597T3 (pt)
ES (1) ES2613027T3 (pt)
GB (1) GB2431404A (pt)
IL (2) IL180727A (pt)
MX (1) MX2007002057A (pt)
NO (1) NO342832B1 (pt)
NZ (2) NZ553494A (pt)
PL (1) PL1778720T3 (pt)
PT (2) PT1778720E (pt)
RU (1) RU2396273C2 (pt)
SG (3) SG10201606278UA (pt)
SI (1) SI1778720T1 (pt)
WO (1) WO2006018652A2 (pt)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252737B2 (en) 2004-12-15 2012-08-28 The Regents Of The University Of Colorado Antimicrobial peptides and methods of use
US9181303B2 (en) 2005-12-22 2015-11-10 Novabiotics Limited Treatment of bacterial infections with cyclic antimicrobial peptides
KR101413746B1 (ko) 2005-12-22 2014-07-01 노바바이오틱스 리미티드 고리형 항균 펩타이드
AU2012203804B2 (en) * 2005-12-22 2014-10-16 Novabiotics Limited Cyclic antimicrobial peptides
GB0702020D0 (en) 2007-02-02 2007-03-14 Novabiotics Ltd Peptides and their use
GB0702022D0 (en) * 2007-02-02 2007-03-14 Novabiotics Ltd Peptides and their use
GB0702021D0 (en) 2007-02-02 2007-03-14 Novabiotics Ltd Peptides and their use
DK2178549T3 (en) * 2007-07-26 2017-01-09 Revance Therapeutics Inc Antimicrobial peptide AND COMPOSITIONS THEREOF
US20100150985A1 (en) * 2008-04-24 2010-06-17 George Just Dental Implant, Endodontic Instrument, and Dental Filling Material Coated with a Peptide-Based Antimicrobial and Methods of Using and Making the Same
GB0817121D0 (en) * 2008-09-18 2008-10-29 Univ St Andrews Anti-fungal therapy
WO2010042534A1 (en) * 2008-10-06 2010-04-15 The Regents Of The University Of Colorado, A Body Corporate Peptides and methods of use
AU2009313615B2 (en) * 2008-11-05 2012-11-29 Regents Of The University Of Minnesota Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (BHS) disease
US8303962B2 (en) * 2009-01-06 2012-11-06 C3 Jian, Inc. Antibacterial and antifungal peptides
FR2941231B1 (fr) 2009-01-16 2016-04-01 Sederma Sa Nouveaux peptides, compositions les comprenant et utilisations cosmetiques et dermo-pharmaceutiques.
GB0905451D0 (en) * 2009-03-31 2009-05-13 Novabiotics Ltd Biofilms
EP2437770A4 (en) * 2009-06-05 2013-11-06 Univ Colorado Regents ANTIMICROBIAL PEPTIDES
JP5664992B2 (ja) * 2009-08-26 2015-02-04 国立大学法人名古屋大学 細胞特異的ペプチド及びその用途
EP2547700A1 (en) * 2010-03-17 2013-01-23 Universität Regensburg Peptides or antibodies which bind to melanoma inhibitory activity (mia) protein
CN102206250B (zh) 2010-03-29 2017-03-15 翔升科技股份有限公司 低血球溶解性的抗微生物肽、药物组合物及其用途
GB201016733D0 (en) 2010-10-05 2010-11-17 Novabiotics Ltd Compounds and their use
GB201021186D0 (en) 2010-12-14 2011-01-26 Novabiotics Ltd Composition
RU2449805C1 (ru) 2011-01-27 2012-05-10 Общество С Ограниченной Ответственностью "Гармония" Пептидная фармацевтическая композиция, средство на ее основе для лечения гастродуоденальных заболеваний, вызываемых helicobacter pylori, и способ его использования
ES2679995T3 (es) 2011-03-11 2018-09-03 Vib Vzw Moléculas y métodos para la inhibición y detección de proteínas
DE102011077071A1 (de) * 2011-06-07 2012-12-13 Beiersdorf Ag Wirkstoffkombinationen aus Epsilon-Polylysin und Climbazol
KR101345333B1 (ko) * 2011-12-30 2013-12-30 조선대학교산학협력단 라이신 및 트립토판 잔기가 ４번 반복된 신규한 항균 및 항진균 펩타이드 및 이의 용도
GB201204457D0 (en) * 2012-03-14 2012-04-25 Novabiotics Ltd Polypeptides and their use
WO2013142184A1 (en) 2012-03-19 2013-09-26 Yale University Antimicrobial compositions and methods
MX344635B (es) 2012-03-23 2017-01-04 Amicrobe Inc Composiciones y usos de materiales antimicrobianos con propiedades compatibles con el tejido.
WO2014066916A2 (en) 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and methods for safe treatment of rhinitis
EP2958429A4 (en) * 2013-02-20 2016-10-05 Biolog Inc COMPOSITIONS AND METHODS FOR INACTIVATION AND / OR REDUCTION OF MICROBIAL TOXIN PRODUCTION
RU2683651C2 (ru) * 2013-06-18 2019-04-01 Иван Дмитриевич Захаров Лекарственное средство для лечения кератоконуса и других дегенеративных заболеваний роговицы и фармацевтические препараты на его основе
GB201409451D0 (en) 2014-05-28 2014-07-09 Ipabc Ltd Antimicrobial preparations, methods for preparing the same and uses thereof to combat microorganisms
WO2015195458A1 (en) * 2014-06-17 2015-12-23 Albert Einstein College Of Medicine, Inc. Therapeutic nanoparticles and methods thereof
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
GB201416727D0 (en) * 2014-09-22 2014-11-05 Novabiotics Ltd Use
CN104311627B (zh) * 2014-10-29 2018-04-10 中山大学 一种抗菌肽的合成方法和应用
EP3106172B1 (de) * 2015-06-15 2020-08-05 B. Braun Melsungen AG Antimikrobiell aktive mittel und deren verwendung
DK3416669T3 (da) * 2016-02-19 2025-08-18 Klaus Brandenburg Midler og metoder til behandling af bakterielle infektioner
PT3554474T (pt) 2016-12-16 2024-02-12 Baxter Healthcare Sa Composições de micafungina
US11045519B2 (en) 2017-01-31 2021-06-29 Unm Rainforest Innovations Arginine-rich polypeptide compositions and methods of using same
CN110740744A (zh) 2017-04-06 2020-01-31 艾麦克罗比公司 性能和安全性增强的局部施用的抗微生物剂的组合物和应用
US11931333B1 (en) * 2019-05-28 2024-03-19 Peter Van Horn Topical treatment of herpes infections
CN112457375B (zh) * 2019-09-06 2022-12-02 韩苏 多肽化合物及其制备方法与应用
CN113264987B (zh) * 2021-05-31 2023-11-17 安徽农业大学 具有抗真菌和清除自由基活性的环色-苏-缬-异亮-亮肽及制备方法
CN113307848B (zh) * 2021-05-31 2023-11-17 安徽农业大学 具有抗真菌和清除自由基活性的环色-丝-缬-异亮-亮肽及制备方法
TW202317598A (zh) * 2021-09-01 2023-05-01 美商艾姆麥克斯治療股份有限公司 具有抗微生物活性的胜肽
CN115669843A (zh) * 2022-10-26 2023-02-03 中国农业大学 一种采用高压微射流结合混合肽有效杀灭芽孢的方法
CN116332777A (zh) * 2023-02-20 2023-06-27 华中科技大学 二芳基苯甲胺类化合物、制备及作为载体合成多肽的应用
GB202311426D0 (en) * 2023-07-25 2023-09-06 Novabiotics Ltd Cosmetic nail formulations
GB202400182D0 (en) * 2024-01-05 2024-02-21 Novabiotics Ltd Improved compositions to improve the appearance and/or condition of skin, scalp, nail and/or hair
WO2026038945A1 (en) * 2024-08-16 2026-02-19 Winnox Cosmeceutics Sdn. Bhd. Peptides, compositions and methods of use
CN119235837B (zh) * 2024-12-02 2025-03-25 温州医科大学附属第一医院 一种专用于抗浅部真菌细菌感染的组合物及其制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3561444A (en) 1968-05-22 1971-02-09 Bio Logics Inc Ultrasonic drug nebulizer
US3703173A (en) 1970-12-31 1972-11-21 Ted A Dixon Nebulizer and tent assembly
US4051842A (en) 1975-09-15 1977-10-04 International Medical Corporation Electrode and interfacing pad for electrical physiological systems
DE2626348C3 (de) 1976-06-11 1980-01-31 Siemens Ag, 1000 Berlin Und 8000 Muenchen Implantierbare Dosiereinrichtung
JPH0340130B2 (pt) 1980-10-14 1991-06-18
US4383529A (en) 1980-11-03 1983-05-17 Wescor, Inc. Iontophoretic electrode device, method and gel insert
US4635627A (en) 1984-09-13 1987-01-13 Riker Laboratories, Inc. Apparatus and method
US4624251A (en) 1984-09-13 1986-11-25 Riker Laboratories, Inc. Apparatus for administering a nebulized substance
US4962091A (en) 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
EP0400372B1 (de) * 1989-05-30 1995-08-02 Siemens Aktiengesellschaft CMOS-ECL-Wandler
CA2061862A1 (en) * 1991-03-04 1992-09-05 Jonathan Duvick Natural and synthetic proteins with inhibitory activity towards pathogenic microorganisms
JP3022615B2 (ja) * 1991-03-13 2000-03-21 日清製粉株式会社 ε−ポリリジンの製造方法
JP3000490B2 (ja) * 1991-04-08 2000-01-17 チッソ株式会社 抗白癬菌剤
WO1994007529A1 (en) 1992-09-25 1994-04-14 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5486503A (en) * 1991-11-01 1996-01-23 The Trustees Of Boston University Anti-fungal histatin-based peptides
JP3655359B2 (ja) * 1995-06-29 2005-06-02 株式会社サンコンタクトレンズ 含水性ソフトコンタクトレンズの洗浄および消毒用組成物
US5714577A (en) * 1996-01-26 1998-02-03 University Of Pittsburgh Antimicrobial peptides
US6503881B2 (en) 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
JPH11113779A (ja) * 1997-10-14 1999-04-27 Asahi Chem Ind Co Ltd 除菌ウェットティッシュ
EA200101086A1 (ru) * 1999-04-15 2002-04-25 Эли Лилли Энд Компани Антигрибковые агенты, выделенные из pseudomonas syringae
US20020001582A1 (en) * 1999-04-21 2002-01-03 Charter Edward A. Methods and compositions for inhibiting microbial growth
JP2001264707A (ja) * 2000-03-22 2001-09-26 Chisso Corp コンタクトレンズ用消毒保存用溶液
JP2002020320A (ja) * 2000-06-30 2002-01-23 Santen Pharmaceut Co Ltd 点眼液用防腐剤
FR2811666B1 (fr) * 2000-07-13 2005-04-01 Entomed S A Peptides antifongiques et/ou antibacteriens, leurs preparations et les compositions les contenant
CN1336383A (zh) * 2000-07-29 2002-02-20 中国科学院昆明动物研究所 大蹼铃蟾抗菌肽及其制备方法和在制药中的应用
RU2183643C1 (ru) * 2000-12-18 2002-06-20 Государственный научно-исследовательский институт особо чистых биопрепаратов Пептид, обладающий биоцидной активностью
US7033991B2 (en) * 2001-07-16 2006-04-25 Board Of Supervisors Of Louisiana State University And Agriculture And Mechanical College Inhibiting furin with polybasic peptides
AU2003231471A1 (en) * 2002-04-25 2003-11-10 Toagosei Co., Ltd. Antimicrobial polypeptide and utizliation thereof
JP4461727B2 (ja) * 2003-07-18 2010-05-12 チッソ株式会社 外用剤組成物
US20080193616A1 (en) * 2007-02-13 2008-08-14 The Coca-Cola Company Beverage compositions comprising polylysine and at least one weak acid

Also Published As

Publication number Publication date
US20070244044A1 (en) 2007-10-18
NO342832B1 (no) 2018-08-13
EP3147293B1 (en) 2022-05-04
PT1778720E (pt) 2010-11-29
AU2005273638B2 (en) 2011-09-29
KR20070083486A (ko) 2007-08-24
ATE479704T1 (de) 2010-09-15
NO20071369L (no) 2007-05-04
EP1778720B1 (en) 2010-09-01
GB0703060D0 (en) 2007-03-28
ES2613027T3 (es) 2017-05-22
JP5020078B2 (ja) 2012-09-05
JP2008509980A (ja) 2008-04-03
KR101234780B1 (ko) 2013-02-20
WO2006018652A3 (en) 2006-07-13
EP2096118A1 (en) 2009-09-02
SG10201606278UA (en) 2016-09-29
CA2575058A1 (en) 2006-02-23
HK1105982A1 (en) 2008-02-29
PL1778720T3 (pl) 2011-03-31
DK1927597T3 (en) 2017-02-13
US8088888B2 (en) 2012-01-03
US7847059B2 (en) 2010-12-07
DE602005023315D1 (de) 2010-10-14
US20110269673A1 (en) 2011-11-03
US8470769B2 (en) 2013-06-25
MX2007002057A (es) 2007-07-19
BRPI0514420B1 (pt) 2022-05-17
DK1778720T3 (da) 2010-11-29
CN101031583B (zh) 2013-06-05
SI1778720T1 (sl) 2011-04-29
EP3147293A1 (en) 2017-03-29
NZ584340A (en) 2010-09-30
US20120071398A1 (en) 2012-03-22
IL180727A (en) 2015-06-30
EP1927597B1 (en) 2016-11-02
US8350003B2 (en) 2013-01-08
CA2575058C (en) 2017-09-12
IL213319A0 (en) 2011-07-31
US20110021415A1 (en) 2011-01-27
CY1113684T1 (el) 2016-06-22
SG155211A1 (en) 2009-09-30
WO2006018652A2 (en) 2006-02-23
IL213319A (en) 2017-07-31
EP3141559A1 (en) 2017-03-15
CN101031583A (zh) 2007-09-05
IL180727A0 (en) 2007-06-03
SG188092A1 (en) 2013-03-28
RU2396273C2 (ru) 2010-08-10
RU2007109518A (ru) 2008-09-27
CA2974538A1 (en) 2006-02-23
PT1927597T (pt) 2017-02-10
EP1778720A2 (en) 2007-05-02
NZ553494A (en) 2010-07-30
CN103360486A (zh) 2013-10-23
GB2431404A (en) 2007-04-25
CN103360485A (zh) 2013-10-23
AU2005273638A1 (en) 2006-02-23
EP1927597A1 (en) 2008-06-04

Similar Documents

Publication Publication Date Title
IL213319A (en) Polylysis peptides for use in the treatment of bacterial infections
BRPI0412761A (pt) inibidores de serino proteases, particularmente a protease ns3-ns4a do vhc
BRPI0515896A (pt) composto ou um sal ou éster farmaceuticamente aceitável do mesmo, método para o tratamento ou profilaxia de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus, e, composição farmacêutica para o tratamento de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus
BR0309498A (pt) Compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças que são relacionadas com o ras, e, uso de compostos
BR0012590A (pt) Composto, processo para a preparação do mesmo, formulação farmacêutica, uso de um composto, e, métodos para tratamento ou profilaxia de dor ou desconforto, e para tratamento ou profilaxia de dor neuropática ou central
BRPI0409227B8 (pt) "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)"
BRPI0306993B8 (pt) polímero de polialquilenoglicol ativado; composição; e uso de um composto na produção de um medicamento para o tratamento de esclerose múltipla ou infecção viral suscetível
MY147643A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
BRPI0410316A (pt) composto, composição farmacêutica, uso dos compostos, e, método de tratamento de distúrbios mediados por vr1 e para o tratamento de distúrbios de dores
ATE427116T1 (de) Behandlung von bakteriellen infektionen
BR0211118A (pt) Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
BR0111989A (pt) Peptìdeos, composições e processos para o tratamento de burkholderia cepacia
BRPI0409884A (pt) compostos, composições farmacêuticas, método para o tratamento ou porfilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
BRPI0409818A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
BR0006301A (pt) Macrólidos antibacterianos e pró-cinéticos
BRPI0407271A (pt) Composição anti-helmìntica
GB0623258D0 (en) Thiadiazole derivatives for the treatment of neuro-degenerative diseases
WO2009070564A3 (en) Compositions and methods for prevention of infection in transcutaneous osseointegrated implants
BRPI0512951A (pt) compostos, processo para sua fabricação, composições farmacêuticas contendo os mesmos, uso e método para tratamento e/ou prevenção de doenças que são moduladas pelos agonistas de ppar(delta) e/ou ppar(alpha)
BR0014751A (pt) Composto, estereoisÈmero ou mistura de estereoisÈmeros, composição farmacêutica, método de tratamento de um paciente em necessidade de tratamento antimicrobiano, e, uso de um composto
BR0308734A (pt) Composto, composição farmacêutica, uso do composto, e, método para prevenir ou tratar infecção

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/08/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2845 DE 15-07-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.